News
|
Announcements
Center for Development and Production of Highly Potent Drugs
TZF Polfa, a Polish pharmaceutical manufacturer, proudly presents its latest investment located in Warsaw – the Center for Development and Production of Highly Potent Drugs, one of the…
Read more
|
Announcements
Distribution of PolhuminPen injectors
Dear Patients and Doctors, Please be advised that PolhuminPen® injectors are distributed free of charge exclusively as part of a patient program for individuals requiring insulin therapy. To…
Read more
|
Announcements
Success in the development of the medicinal product Dapagliflozinum 10 mg
We are pleased to announce that the newly developed medicinal product Dapagliflozinum, 10 mg, coated tablets, has successfully passed bioequivalence testing. The project is co-financed from the state…
Read more
|
Tenders
Request for quotation – RFQZ79/5914/1 – Bioequivalence study: Empagliflozinum, 25 mg, coated tablets
In connection with the implementation of project 2022/ABM/04/00014-00 – “Development and advancement of a medicinal product with the active substance EMPAGLIFLOZIN – a generic drug for type 2…
Read more
|
Message for the patient
Availability of Elenium
Warsaw, October 7, 2025 Dear Sir or Madam, In connection with the administrative decision of the Main Pharmaceutical Inspectorate concerning the withdrawal from the market of specific batches…
Read more
|
Announcements
Distribution of PolhuminPen injectors
Please note that inquiries regarding the free distribution of PolhuminPen should be sent directly to: wstrzykiwacze@tzf.pl. For more information, please call: +48 (22) 510 80 01.
Read more